It’s been a busy morning for Paragon Labs. In addition to bringing over much of the leadership team from AbbVie-acquired ...

Human genetic studies have linked ALK7 variants to reduced waist-to-hip ratios—a measure of abdominal obesity—and inactivating ALK7 signaling makes mice resistant to obesity. This research has ...

Insulet Corporation has announced the U.S. full market release of Omnipod Discover, a web-based data platform designed for ...

Merck & Co. has poured out its Brunello data, revealing a mix of undifferentiated efficacy and concerning safety that led ...

Bristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth. | Bristol Myers Squibb has reported phase 3 wins in a ...

Tortugas Neuroscience’s schizophrenia drug from Hansoh Pharma has proven its worth in a phase 2b study, validating the ...

Parkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug ...

One year on from a mixed phase 3 readout, Roche has shared updated data from eye disease trials that could support FDA ...

Endeavor BioMedicines has solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing ...

GSK has joined Chai Discovery’s growing roster of Big Pharma clients, signing up to access protein-folding and design models.

As a notorious night owl, it was already very early in the morning of October 5 when Karl Deisseroth, M.D., Ph.D., finally ...

Caribou Biosciences, the off-the-shelf cell therapy outfit that spun out of Nobel Laureate Jennifer Doudna’s lab in 2011, is ...